Chemomab Therapeutics (CMMB) Return on Invested Capital (2018 - 2019)

Chemomab Therapeutics' (CMMB) quarterly Return on Invested Capital came in at 0.01% in Q3 2019, up 11.35% on a QoQ basis from 0.01% in Q2 2019.

Chemomab Therapeutics (CMMB) Return on Invested Capital (2018 - 2019) Analysis & Trends

Chemomab Therapeutics (CMMB) has 2 years of Return on Invested Capital data on file, last reported at 0.01% in Q3 2019.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.01% in Q3 2019, while the trailing twelve-month figure through Sep 2019 was 0.01% (changed N/A YoY) and the FY2018 annual result came in at 0.02%, changed N/A from the prior year.
Return on Invested Capital climbed to 0.01% in Q3 2019, from 0.01% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.02% in Q4 2018 to a low of 0.01% in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.04%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.17%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Chemomab Therapeutics	13.62 Mn	3.25 Mn	-	-

Download Data